Cost-Effectiveness Evaluation of Brentuximab Vedotin for Refractory/Relapsed Hodgkin Lymphoma- A Comparative Analysis of the Results of Mexico and Venezuela
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2290
https://www.valueinhealthjournal.com/article/S1098-3015(14)04220-X/fulltext
Title :
Cost-Effectiveness Evaluation of Brentuximab Vedotin for Refractory/Relapsed Hodgkin Lymphoma- A Comparative Analysis of the Results of Mexico and Venezuela
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04220-X&doi=10.1016/j.jval.2014.08.2290
First page :
A637
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1749